|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
HCC cell line HepG2 was infected with Ad-CYP2E1 to enhance the expression of CYP2E1, followed by treatment with low toxic dose of recombinant human Fas ligand (FasL, 0.5 ng/ml) in the presence of Actinomycin D (Act D, 125 ng/ml).
|
18497573 |
2008 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
CYP2E1 Pst I/Rsa I polymorphism may contribute to the proportion cases of HCC, which needs further investigations.
|
25185993 |
2014 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
CYP2E1 may be an attractive target for enhanced antitumor effects of VK2 in hepatocellular carcinoma treatment.
|
28339022 |
2017 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Acetaldehyde dehydrogenase 2 (<i>ALDH2</i>) and cytochrome P450 2E1 (<i>CYP2E1</i>) have been associated with hepatocellular carcinoma (HCC) susceptibility and prognosis.
|
29765251 |
2018 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
ALDH2 and CYP2E1 polymorphisms may modify the risk of development of HCC against the background of LC in the Japanese.
|
12940444 |
2003 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Among the 27 CYPs, levels of 7 (CYP2B6, CYP-IIC, CYP2C9, CYP2C19, CYP3A5, CYP4F3 and CYP27A1) were significantly lower and levels of 2 (CYP2E1 and CYP4F2) were slightly lower in HCC with venous invasion than in HCC without venous invasion.
|
16077914 |
2005 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Compared to controls, Cyp2E1 rsaI variant c2 genotype increased the risk of HBV related liver disease severity by 2.68 fold, the highest for HCC cases (3.981 folds, p=0.106); and was associated with higher histology activity index (HAI) (p<0.001) in CHBV patients.
|
23454624 |
2013 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Finally, the influence of CYP2E1, GSTM1, or the combined at-risk genotype on the risk of hepatocellular carcinoma in smokers is briefly discussed.
|
9255556 |
1997 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Herein, CYP2E1 activity and content were determined in fibrotic liver tissue from patients with hepatocellular carcinoma.
|
29348818 |
2017 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Herein, we measured CYP2E1 activity and the expression of CD163 (an M2 marker) and CD68 (a pan-macrophage marker) in hepatofibrotic tissue from HCC patients (n = 26) with comparison to normal liver tissue (n = 26).
|
31116889 |
2019 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Human hepatoma HepG2 cells with transduced CYP2E1 (E47 cells) were used as a model to generate ROS through CYP2E1-mediated ethanol metabolism.
|
15449375 |
2004 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Importantly, however, hepatofibrotic rats with higher CYP2E1 activity developed a more severe form of HCC.
|
29917271 |
2018 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In contrast to results with HepG2 cells expressing CYP2E1, no increase in GCS-HS mRNA was found with a HepG2 cell line engineered to express human cytochrome P450 3A4.
|
10748080 |
2000 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
In the progression of cirrhosis and HCC, the expression level of CYP2E1 was gradually decreased and hardly detected until the late stage of HCC.
|
15162526 |
2004 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In the progression of cirrhosis and HCC, the expression level of CYP2E1 was gradually decreased and hardly detected until the late stage of HCC.
|
15162526 |
2004 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
In the progression of cirrhosis and HCC, the expression level of CYP2E1 was gradually decreased and hardly detected until the late stage of HCC.
|
15162526 |
2004 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
No association with the risk of HCC was observed for the DraI polymorphism of CYP2E1 or for the GSTM1-null genotype.
|
7557094 |
1995 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our data showed that TSA selectively induced CYP2E1 in four studied human hepatocellular carcinoma (HCC) cell lines (Huh7, PLC/PRF/5, Hep3B and HepG2), but not in normal primary human hepatocytes.
|
20404016 |
2010 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Recently, down-expression of CYP2E1 was found in hepatocellular carcinoma (HCC) with the majority to be chronic hepatitis B virus (HBV) carriers.
|
25238230 |
2014 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The CYP2E1 5'-flanking regions of the human (-3712 bp to +10 bp) and rat (-3685 bp to +28 bp) genes were ligated in front of a luciferase reporter gene and transfected into rat hepatoma Fao and human hepatoma B16A2 cells.
|
10491286 |
1999 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
LHGDN |
The aim of this study was to determine whether hepatitis C virus core protein and alcohol-inducible cytochrome P450 2E1 contribute to reactive oxygen species production and cytotoxicity in human hepatoma cells.
|
15633127 |
2005 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The carrier state of one copy of the c2 CYP2E1 gene increases the risk of hepatoma in previously regular ethanol users with chronic liver disease.
|
8977352 |
1996 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The effect of genetic polymorphisms for glutathione S-transferase ( GST) M1, GSTT1, GSTP1-1( GSTP1), cytochrome P450 2E1 ( CYP2E1) and aldehyde dehydrogenase 2 ( ALDH2) on the risk of hepatocellular carcinoma (HCC) was observed in 78 Japanese patients with HCC and 138 non-cancer hospital controls.
|
12759747 |
2003 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The high-activity CYP2E1 c2 allele was underrepresented among HCC patients with respect to other HCV categories, including cirrhosis.
|
12569554 |
2003 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The meta-analysis indicated that CYP2E1 Pst I/Rsa polymorphism was not associated with HCC risk, while the interaction between Pst I/Rsa polymorphism and alcohol consumption increased the risk of HCC.
|
22249978 |
2012 |